Collaboration

Novartis forms alliance to develop medicines for treating infectious diarrheal disease

February 14, 2018

Basel, February 14, 2018 -Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance development of Novartis’ drug candidate KDU731 for the treatment of cryptosporidiosis. Diarrheal diseases are one of the leading causes of childhood mortality globally, resulting in approximately 525,000 deaths each year and cryptosporidiosis is the second leading cause […]

Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment

February 14, 2018

MIAMI LAKES, Fla., Feb. 14, 2018 (GLOBE NEWSWIRE) — Regentys (formerly Asana Medical, Inc.), a regenerative medicine company, today announced it will partner with Cook Biotech Inc., a world leader in cost-effective, advanced tissue-repair products, to develop a novel treatment for ulcerative colitis. Under the terms of a signed letter of intent, Cook Biotech will […]

Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214

February 14, 2018

NEW YORK & SAN FRANCISCO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar’s lead immuno-oncology program, NKTR-214. Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) […]

Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb

February 13, 2018

SAN DIEGO, Feb. 12, 2018 /PRNewswire/ — Sirenas, LLC (“Sirenas”), a biotechnology company harnessing computational approaches to discover therapeutics derived from the global microbiome, announced today that it has entered into a multi-target research collaboration agreement with Bristol-Myers Squibb to deploy Sirenas’ drug discovery platform against certain undisclosed challenging therapeutic targets to identify potential drug […]

Science Exchange Announces Outsourced R&D Collaboration with UC Davis Venture Catalyst Group

February 13, 2018

Palo Alto, CA – February 12, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic collaboration with Venture Catalyst, a unit within the Technology Management and Corporate Relations division of the UC Davis Office of Research which supports the development of new […]

Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide

February 12, 2018

BASEL, Switzerland & LYON, France–(BUSINESS WIRE)–Roivant Sciences, a global healthcare company focused on realizing the full value of promising biomedical research, and POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders including type 2 diabetes, today announced the signing of a strategic development and license […]

Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide

February 12, 2018

BASEL, Switzerland and LYON, France, February 12, 2018 – Roivant Sciences, a global healthcare company focused on realizing the full value of promising biomedical research, and POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders including type 2 diabetes, today announced the signing of a […]

Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

February 9, 2018

BOSTON & BOTHELL, Wash.–(BUSINESS WIRE)–Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company developing innovative, targeted therapies for cancer, today announced they have entered into a collaboration and license agreement […]

Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma Haichang to fund development through completion of Phase IIa Proof-of-Concept Clinical Trial

February 8, 2018

ROCKVILLE, Md., Feb. 08, 2018 (GLOBE NEWSWIRE) — Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd. (Haichang), to develop RX-0201 (Archexin®) for the treatment of hepatocellular […]

Portage ‘s PPL forms a joint venture with University of Glasgow to develop new peptide therapeutics

February 2, 2018

TORONTO, Feb. 2, 2018 /PRNewswire/ – Portage Biotech Inc. (“Portage”) (OTCQB: PTGEF, Canadian Stock Exchange: PBT.U) is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. (“PPL’), has formed a new joint venture company, Portage Glasgow Limited (“PGL”), incorporated in Scotland, to develop more effectively-targeted drugs to treat chronic conditions including cancer.   […]

Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis

February 2, 2018

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced an agreement with the Institute of Integrative Biology at the University of Liverpool to collaborate on research to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment […]

Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis

February 1, 2018

SAN DIEGO, Feb. 01, 2018 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) and the Mycoses Study Group Education and Research Consortium (MSGERC) today announced the establishment of a collaboration to advance Vical’s novel antifungal drug product candidate for the treatment of invasive aspergillosis. This collaboration will combine the clinical development expertise of Vical with the specialized […]

Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

February 1, 2018

WALTHAM, Mass., Feb. 1, 2018 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s durvalumab, a human monoclonal antibody directed against programmed death-ligand 1 […]

BioPontis Alliance for Rare Diseases Announces Agreement with Massachusetts General Hospital on New Treatments for Huntington’s Disease

February 1, 2018

RALEIGH, N.C. & BRUSSELS & BOSTON–(BUSINESS WIRE)–Today, BioPontis Alliance for Rare Diseases, an international nonprofit organization, and Massachusetts General Hospital (MGH), the largest hospital-based research program in the United States, announce an agreement initially targeting the treatment of Huntington’s disease. The mission of BioPontis Alliance is to advance promising basic research into treatments for rare […]

PharmAbcine Enters Collaboration with MSD Focused on Clinical Evaluation of TTAC-0001 in Combination with KEYTRUDA® (pembrolizumab) in Recurrent Glioblastoma and Breast Cancer

February 1, 2018

DAEJEON, South Korea–(BUSINESS WIRE)–PharmAbcine Inc., a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications, announces it has entered into a collaborative agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA), through a subsidiary, to evaluate PharmAbcine’s anti-VEGFR2 mAb, TTAC-0001, in combination with MSD’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® […]

Elsevier Welcomes Six Biotech and Pharma Start-ups to The Hive, Supporting the Most Cutting-edge Research in Industry

January 31, 2018

Start-ups working on a range of technologies and discoveries – from AI to immunotherapy – receive complimentary access to Elsevier’s information solutions to accelerate innovation Elsevier, the global information analytics business specializing in science and health, today announced that six start-up companies have been selected from more than 150 global applicants for The Hive, Elsevier’s innovation initiative for biotech and pharmaceutical start-ups. Exscientia, LegoChem Biosciences, 4P-Pharma, […]

Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

January 26, 2018

MENLO PARK, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to […]

Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis

January 25, 2018

BEDFORD, Mass.–(BUSINESS WIRE)–A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, and the Institute for Applied […]

Bridging Clinical Collaborative Patient Advocacy Breakfast Fosters Solutions to Integrate Clinical Research Into Health Care

January 25, 2018

Kearney, Neb., Jan. 25, 2018 (Business Wire) — The Bridging Clinical Research & Clinical Health Care Collaborative, a strategic forum for clinical research and health care professionals to come together to bridge the gap between clinical research and health care, will host a patient advocacy breakfast April 5 in National Harbor, Md. Organized by John […]

Nanome Partners with Science Exchange to Offer Virtual Reality Drug Design Tools and Blockchain Solutions to Scientists

January 24, 2018

Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with Nanome Inc. to offer scientists on-demand access to Nanome’s blockchain and virtual reality technology. Nanome is a San Diego-based company whose mission is to democratize science through blockchain technology and virtual reality tools to […]

Innovative Targeting Solutions Announces Research Agreement with Lilly

January 23, 2018

VANCOUVER, Jan. 22, 2018 /CNW/ – Innovative Targeting Solutions Inc. (ITS) today announced a research agreement with Eli Lilly and Company. Under the agreement, Innovative Targeting Solutions’ will utilize its proprietary HuTARG™ research platform to potentially discover first in class antibody drug candidates. The HuTARG™ protein engineering platform allows one to directly isolate and engineer […]

Vyripharm and WardMM announce clinical trial partnership for the integration of traditional standard pharmaceuticals with medical botanicals and the application of big data in precision medicine

January 23, 2018

HOUSTON and MELBOURNE, Australia, Jan. 22, 2018 /PRNewswire/ — Vyripharm Biopharmaceutical (VB) announces a collaboration with WardMM, to establish clinical trial partnership/Joint Venture (JV) for the use of medical botanicals in patients. The JV represents a global first in a collaboration to produce comprehensive precision pharmaceutical grade medicine, derived from medical botanicals. The JV is […]

Celsee and IncellDx Sign Co-Commercialization Agreement Following Successful Lung Cancer/CTC PD-L1 Feasibility Study

January 18, 2018

PLYMOUTH, Mich., Jan. 17, 2018 /PRNewswire/ — Celsee, Inc., an innovator of platforms for comprehensive single-cell identification, analysis and retrieval, announced today that they have entered a co-commercialization agreement with IncellDx, Inc., a single-cell diagnostic company offering a pioneering technology platform that enables simultaneous cell classification and single-cell analysis of proteomic and genomic biomarkers.   […]

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

January 18, 2018

Holzkirchen, 18 January 2018 – Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing […]

Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients

January 17, 2018

LIVONIA, Mich., Jan. 17, 2018 (GLOBE NEWSWIRE) — Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it has achieved its enrollment goal of 90 subjects across 39 sites in its Phase 2b INDIGO-1 trial investigating gemcabene in […]

FEEDBACK